Premium
KalVista Pharmaceuticals Inc (KALV)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-27 | Dr. Christopher M. YeaChief Development Officer | -33,80k | 666,26k | Derivative Exercise and Sale | 7,07 - 26,78 | 229,92k | - |
| 2026-05-22 | Dr. Paul K. AudhyaChief Medical Officer | -2,24k | 59,96k | Derivative Exercise and Sale | 26,78 | 150,26k | - |
| 2026-05-22 | Ms. Nicole SweenyChief Commercial Officer | 3,51k | 0,00 | Derivative Exercise and Retained Stock | - | 59,29k | 6,29% |
| 2026-05-22 | Dr. Christopher M. YeaChief Development Officer | 1,16k | 0,00 | Derivative Exercise and Retained Stock | - | 229,92k | 0,51% |
| 2026-05-22 | Dr. Paul K. AudhyaChief Medical Officer | 2,76k | 0,00 | Derivative Exercise and Retained Stock | - | 150,26k | 1,87% |
| 2026-05-22 | Ms. Nicole SweenyChief Commercial Officer | -1,49k | 39,87k | Derivative Exercise and Sale | 26,78 | 59,29k | - |
| 2026-05-22 | Dr. Christopher M. YeaChief Development Officer | -1,97k | 52,65k | Derivative Exercise and Sale | 26,78 | 229,92k | - |
| 2026-05-21 | Mr. Benjamin L. PalleikoCEO & Director | 12,32k | 0,00 | Derivative Exercise and Retained Stock | - | 479,99k | 2,64% |
| 2026-05-21 | Mr. Benjamin L. PalleikoCEO & Director | -10,93k | 292,65k | Derivative Exercise and Sale | 26,78 | 479,99k | - |
| 2026-05-21 | Ms. Nicole SweenyChief Commercial Officer | 4,39k | 0,00 | Derivative Exercise and Retained Stock | - | 55,78k | 8,54% |
| 2026-05-21 | Ms. Nicole SweenyChief Commercial Officer | -1,86k | 49,85k | Derivative Exercise and Sale | 26,78 | 55,78k | - |
| 2026-05-21 | Dr. Christopher M. YeaChief Development Officer | 1,39k | 0,00 | Derivative Exercise and Retained Stock | - | 228,76k | 0,61% |
| 2026-05-21 | Dr. Christopher M. YeaChief Development Officer | -2,36k | 63,16k | Derivative Exercise and Sale | 26,78 | 228,76k | - |
| 2026-05-21 | Mr. Brian PiekosCFO | 3,51k | 0,00 | Derivative Exercise and Retained Stock | - | 21,66k | 19,34% |
| 2026-05-21 | Mr. Brian PiekosCFO | -1,49k | 39,88k | Derivative Exercise and Sale | 26,78 | 21,66k | - |
| 2026-05-21 | Dr. Paul K. AudhyaChief Medical Officer | 3,57k | 0,00 | Derivative Exercise and Retained Stock | - | 147,50k | 2,48% |
| 2026-05-21 | Dr. Paul K. AudhyaChief Medical Officer | -2,69k | 71,92k | Derivative Exercise and Sale | 26,78 | 147,50k | - |
| 2026-05-06 | Frazier Life Sciences Management, LPSociété | -3,13M | 83,87M | Vente | 26,77 - 26,78 | 1,83M | -63,13% |
| 2026-05-17 | Dr. Christopher M. YeaChief Development Officer | 666,00 | 0,00 | Derivative Exercise and Retained Stock | - | 227,37k | 0,29% |
| 2026-05-17 | Dr. Christopher M. YeaChief Development Officer | -1,11k | 29,65k | Derivative Exercise and Sale | 26,76 | 227,37k | - |
| 2026-05-17 | Dr. Paul K. AudhyaChief Medical Officer | 1,39k | 0,00 | Derivative Exercise and Retained Stock | - | 143,93k | 0,97% |
| 2026-05-17 | Dr. Paul K. AudhyaChief Medical Officer | -1,03k | 27,62k | Derivative Exercise and Sale | 26,76 | 143,93k | - |
| 2026-05-17 | Mr. Benjamin L. PalleikoCEO & Director | 1,29k | 0,00 | Derivative Exercise and Retained Stock | - | 467,67k | 0,28% |
| 2026-05-17 | Mr. Benjamin L. PalleikoCEO & Director | -1,13k | 30,21k | Derivative Exercise and Sale | 26,76 | 467,67k | - |
| 2026-05-11 | Mr. Benjamin L. PalleikoCEO & Director | 3,80k | 0,00 | Derivative Exercise and Retained Stock | - | 466,38k | 0,82% |
| 2026-05-11 | Mr. Benjamin L. PalleikoCEO & Director | -3,32k | 88,73k | Derivative Exercise and Sale | 26,71 | 466,38k | - |
| 2026-04-16 | Ms. Nicole SweenyChief Commercial Officer | 4,39k | 0,00 | Derivative Exercise and Retained Stock | - | 51,39k | 9,34% |
| 2026-04-16 | Ms. Nicole SweenyChief Commercial Officer | -1,86k | 37,64k | Derivative Exercise and Sale | 20,22 | 51,39k | - |
| 2026-04-16 | Dr. Paul K. AudhyaChief Medical Officer | 3,56k | 0,00 | Derivative Exercise and Retained Stock | - | 142,55k | 2,56% |
| 2026-04-16 | Dr. Paul K. AudhyaChief Medical Officer | -2,69k | 54,30k | Derivative Exercise and Sale | 20,22 | 142,55k | - |
| 2026-04-16 | Mr. Brian PiekosCFO | 4,39k | 0,00 | Derivative Exercise and Retained Stock | - | 18,15k | 31,88% |
| 2026-04-16 | Mr. Brian PiekosCFO | -1,86k | 37,64k | Derivative Exercise and Sale | 20,22 | 18,15k | - |
| 2026-04-16 | Mr. Benjamin L. PalleikoCEO & Director | 10,76k | 0,00 | Derivative Exercise and Retained Stock | - | 462,58k | 2,38% |
| 2026-04-16 | Mr. Benjamin L. PalleikoCEO & Director | -9,55k | 193,07k | Derivative Exercise and Sale | 20,22 | 462,58k | - |
| 2026-03-25 | VR Management, LLCSociété | -214,63k | 3,69M | Vente | 16,95 - 19,12 | 5,09M | -4,05% |
| 2026-03-06 | Mr. Benjamin L. PalleikoCEO & Director | 8,93k | 0,00 | Derivative Exercise and Retained Stock | - | 451,82k | 2,02% |
| 2026-03-06 | Mr. Benjamin L. PalleikoCEO & Director | -6,69k | 107,63k | Derivative Exercise and Sale | 16,08 | 451,82k | - |
| 2026-02-21 | Dr. Paul K. AudhyaChief Medical Officer | 5,90k | 0,00 | Derivative Exercise and Retained Stock | - | 138,98k | 4,43% |
| 2026-02-21 | Dr. Paul K. AudhyaChief Medical Officer | -5,35k | 83,34k | Derivative Exercise and Sale | 15,57 | 138,98k | - |
| 2026-02-21 | Mr. Benjamin L. PalleikoCEO & Director | 13,22k | 0,00 | Derivative Exercise and Retained Stock | - | 442,88k | 3,08% |
| 2026-02-21 | Mr. Benjamin L. PalleikoCEO & Director | -10,03k | 156,20k | Derivative Exercise and Sale | 15,57 | 442,88k | - |
| 2026-02-21 | Ms. Nicole SweenyChief Commercial Officer | 7,28k | 0,00 | Derivative Exercise and Retained Stock | - | 47,00k | 18,31% |
| 2026-02-22 | Ms. Nicole SweenyChief Commercial Officer | -3,98k | 61,88k | Derivative Exercise and Sale | 15,57 | 47,00k | - |
| 2026-02-21 | Dr. Christopher M. YeaChief Development Officer | 2,53k | 0,00 | Derivative Exercise and Retained Stock | - | 226,70k | 1,13% |
| 2026-02-21 | Dr. Christopher M. YeaChief Development Officer | -4,35k | 67,67k | Derivative Exercise and Sale | 15,57 | 226,70k | - |
| 2026-02-21 | Mr. Brian PiekosCFO | 3,23k | 0,00 | Derivative Exercise and Retained Stock | - | 13,76k | 30,71% |
| 2026-02-21 | Mr. Brian PiekosCFO | -1,77k | 27,51k | Derivative Exercise and Sale | 15,57 | 13,76k | - |
| 2026-02-17 | Dr. Paul K. AudhyaChief Medical Officer | 1,26k | 0,00 | Derivative Exercise and Retained Stock | - | 133,09k | 0,95% |
| 2026-02-17 | Dr. Paul K. AudhyaChief Medical Officer | -1,16k | 17,45k | Derivative Exercise and Sale | 15,00 | 133,09k | - |
| 2026-02-17 | Mr. Benjamin L. PalleikoCEO & Director | 1,38k | 0,00 | Derivative Exercise and Retained Stock | - | 429,67k | 0,32% |
| 2026-02-17 | Mr. Benjamin L. PalleikoCEO & Director | -1,04k | 15,57k | Derivative Exercise and Sale | 15,00 | 429,67k | - |
| 2026-02-17 | Dr. Christopher M. YeaChief Development Officer | 665,00 | 0,00 | Derivative Exercise and Retained Stock | - | 224,17k | 0,30% |
| 2026-02-17 | Dr. Christopher M. YeaChief Development Officer | -1,11k | 16,64k | Derivative Exercise and Sale | 15,00 | 224,17k | - |
| 2026-02-11 | Mr. Benjamin L. PalleikoCEO & Director | 3,77k | 0,00 | Derivative Exercise and Retained Stock | - | 428,29k | 0,89% |
| 2026-02-11 | Mr. Benjamin L. PalleikoCEO & Director | -3,35k | 52,66k | Derivative Exercise and Sale | 15,70 | 428,29k | - |
| 2025-12-06 | Mr. Benjamin L. PalleikoCEO & Director | 8,33k | 0,00 | Derivative Exercise and Retained Stock | - | 424,52k | 2,00% |
| 2025-12-06 | Mr. Benjamin L. PalleikoCEO & Director | -7,29k | 120,42k | Derivative Exercise and Sale | 16,51 | 424,52k | - |
| 2025-11-21 | Ms. Nicole SweenyChief Commercial Officer | 7,44k | 0,00 | Derivative Exercise and Retained Stock | - | 39,73k | 23,03% |
| 2025-11-22 | Ms. Nicole SweenyChief Commercial Officer | -3,81k | 51,29k | Derivative Exercise and Sale | 13,45 | 39,73k | - |
| 2025-11-21 | Mr. Brian PiekosCFO | 10,53k | 0,00 | Derivative Exercise and Retained Stock | - | 10,53k | - |
| 2025-11-21 | Mr. Brian PiekosCFO | -4,47k | 60,14k | Derivative Exercise and Sale | 13,45 | 10,53k | - |
| 2025-11-21 | Dr. Christopher M. YeaChief Development Officer | 2,54k | 0,00 | Derivative Exercise and Retained Stock | - | 223,51k | 1,15% |
| 2025-11-21 | Dr. Christopher M. YeaChief Development Officer | -4,33k | 58,26k | Derivative Exercise and Sale | 13,45 | 223,51k | - |
| 2025-11-21 | Dr. Paul K. AudhyaChief Medical Officer | 5,95k | 0,00 | Derivative Exercise and Retained Stock | - | 131,83k | 4,73% |
| 2025-11-21 | Dr. Paul K. AudhyaChief Medical Officer | -5,30k | 71,24k | Derivative Exercise and Sale | 13,45 | 131,83k | - |
| 2025-11-21 | Mr. Benjamin L. PalleikoCEO & Director | 12,31k | 0,00 | Derivative Exercise and Retained Stock | - | 416,19k | 3,05% |
| 2025-11-21 | Mr. Benjamin L. PalleikoCEO & Director | -10,94k | 147,15k | Derivative Exercise and Sale | 13,45 | 416,19k | - |
| 2025-11-20 | Dr. Christopher M. YeaChief Development Officer | 87,39k | 375,78 | Derivative Exercise and Retained Stock | 0,00 | 220,96k | 65,42% |
| 2025-11-17 | Mr. Benjamin L. PalleikoCEO & Director | 4,90k | 0,00 | Derivative Exercise and Retained Stock | - | 403,88k | 1,23% |
| 2025-11-17 | Mr. Benjamin L. PalleikoCEO & Director | -4,47k | 64,67k | Derivative Exercise and Sale | 14,48 | 403,88k | - |
| 2025-11-17 | Dr. Christopher M. YeaChief Development Officer | 1,52k | 0,00 | Derivative Exercise and Retained Stock | - | 133,57k | 1,15% |
| 2025-11-17 | Dr. Christopher M. YeaChief Development Officer | -2,68k | 38,85k | Derivative Exercise and Sale | 14,48 | 133,57k | - |
| 2025-11-17 | Dr. Paul K. AudhyaChief Medical Officer | 3,37k | 0,00 | Derivative Exercise and Retained Stock | - | 125,88k | 2,75% |
| 2025-11-17 | Dr. Paul K. AudhyaChief Medical Officer | -3,08k | 44,52k | Derivative Exercise and Sale | 14,48 | 125,88k | - |
| 2025-11-11 | Mr. Benjamin L. PalleikoCEO & Director | 3,79k | 0,00 | Derivative Exercise and Retained Stock | - | 398,98k | 0,96% |
| 2025-11-11 | Mr. Benjamin L. PalleikoCEO & Director | -3,33k | 38,44k | Derivative Exercise and Sale | 11,55 | 398,98k | - |
| 2025-11-01 | Frazier Life Sciences Management, LPSociété | 973,45k | 0,00 | Achat | - | 3,47M | 39,05% |
| 2025-09-06 | Mr. Benjamin L. PalleikoCEO & Director | 8,33k | 0,00 | Derivative Exercise and Retained Stock | - | 395,19k | 2,15% |
| 2025-09-06 | Mr. Benjamin L. PalleikoCEO & Director | -7,29k | 115,54k | Derivative Exercise and Sale | 15,84 | 395,19k | - |
| 2025-08-22 | Ms. Nicole SweenyChief Commercial Officer | 3,52k | 0,00 | Derivative Exercise and Retained Stock | - | 32,29k | 12,23% |
| 2025-08-22 | Ms. Nicole SweenyChief Commercial Officer | -1,48k | 19,86k | Derivative Exercise and Sale | 13,42 | 32,29k | - |
| 2025-08-22 | Dr. Christopher M. YeaChief Development Officer | 1,17k | 0,00 | Derivative Exercise and Retained Stock | - | 132,05k | 0,89% |
| 2025-08-22 | Dr. Christopher M. YeaChief Development Officer | -1,95k | 26,22k | Derivative Exercise and Sale | 13,42 | 132,05k | - |
| 2025-08-22 | Dr. Paul K. AudhyaChief Medical Officer | 2,66k | 0,00 | Derivative Exercise and Retained Stock | - | 122,51k | 2,22% |
| 2025-08-22 | Dr. Paul K. AudhyaChief Medical Officer | -2,34k | 31,35k | Derivative Exercise and Sale | 13,42 | 122,51k | - |
| 2025-08-21 | Ms. Nicole SweenyChief Commercial Officer | 4,39k | 0,00 | Derivative Exercise and Retained Stock | - | 28,77k | 17,99% |
| 2025-08-21 | Ms. Nicole SweenyChief Commercial Officer | -1,86k | 24,65k | Derivative Exercise and Sale | 13,22 | 28,77k | - |
| 2025-08-21 | Dr. Christopher M. YeaChief Development Officer | 1,39k | 0,00 | Derivative Exercise and Retained Stock | - | 130,88k | 1,07% |
| 2025-08-21 | Dr. Christopher M. YeaChief Development Officer | -2,36k | 31,23k | Derivative Exercise and Sale | 13,22 | 130,88k | - |
| 2025-08-21 | Dr. Paul K. AudhyaChief Medical Officer | 3,31k | 0,00 | Derivative Exercise and Retained Stock | - | 119,84k | 2,84% |
| 2025-08-21 | Dr. Paul K. AudhyaChief Medical Officer | -2,94k | 38,90k | Derivative Exercise and Sale | 13,22 | 119,84k | - |
| 2025-08-21 | Mr. Benjamin L. PalleikoCEO & Director | 12,31k | 0,00 | Derivative Exercise and Retained Stock | - | 386,86k | 3,29% |
| 2025-08-21 | Mr. Benjamin L. PalleikoCEO & Director | -10,94k | 144,66k | Derivative Exercise and Sale | 13,22 | 386,86k | - |
| 2025-08-17 | Dr. Paul K. AudhyaChief Medical Officer | 3,51k | 0,00 | Derivative Exercise and Retained Stock | - | 116,53k | 3,10% |
| 2025-08-17 | Dr. Paul K. AudhyaChief Medical Officer | -2,94k | 38,76k | Derivative Exercise and Sale | 13,19 | 116,53k | - |
| 2025-08-17 | Dr. Christopher M. YeaChief Development Officer | 1,55k | 0,00 | Derivative Exercise and Retained Stock | - | 129,49k | 1,21% |
| 2025-08-17 | Dr. Christopher M. YeaChief Development Officer | -2,65k | 34,93k | Derivative Exercise and Sale | 13,19 | 129,49k | - |
| 2025-08-17 | Mr. Benjamin L. PalleikoCEO & Director | 4,95k | 0,00 | Derivative Exercise and Retained Stock | - | 374,55k | 1,34% |
| 2025-08-17 | Mr. Benjamin L. PalleikoCEO & Director | -4,41k | 58,14k | Derivative Exercise and Sale | 13,19 | 374,55k | - |
| 2025-07-09 | Mr. Benjamin L. PalleikoCEO & Director | -32,98k | 517,52k | Vente | 15,69 | 369,60k | -8,19% |
| 2025-07-09 | Dr. Christopher M. YeaChief Development Officer | -30,25k | 474,70k | Vente | 15,69 | 127,94k | -19,12% |
| 2025-06-06 | Mr. Benjamin L. PalleikoCEO & Director | 8,46k | 0,00 | Derivative Exercise and Retained Stock | - | 315,07k | 2,76% |
| 2025-06-06 | Mr. Benjamin L. PalleikoCEO & Director | -7,17k | 103,95k | Derivative Exercise and Sale | 14,50 | 315,07k | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
